Gland Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026, inter alia, to consider and approve Unaudited Standalone and Consolidated Financial results of the Company for the quarter ended June 30, 2026.
The above information is a part of company’s filings submitted to BSE.